• International Flavors has exceeded net sales estimates in the first quarter, with sales amounting to $2.90 billion.
• Despite witnessing a decrease of -4.2% y/y, the sales stand higher than the estimated $2.78 billion.
• Nourish net sales reached $1.50 billion, showing a decrease of -9.5% y/y but surpassing the estimated figure of $1.43 billion.
• Health & Biosciences nets sales saw an uptick, posting at $531 million (+3.5% y/y), higher than the estimated $515.1 million.
• Scent net sales witnessed an increase reporting sales of $645 million (+6.1% y/y), outperforming the estimate of $597.8 million.
• Pharma Solutions’ net sales, on the other hand, went down by -10% y/y to $227 million, which is also lower than the estimated $236.9 million.
• The Company's 1Q adjusted EPS excluding amortization stood at $1.13, which shows an increase from the previous year and comfortably beats the estimated 82c.
• Adjusted operating Ebitda was $578 million, marking a 15% y/y increase and exceeding estimates of $491.3 million.
• International Flavors forecasts full-year 2024 results to appear towards the higher end of its previously announced sales guidance range of $10.8 billion to $11.1 billion and adjusted operating EBITDA guidance range of $1.9 billion to $2.1 billion.
• This optimistic outlook is based on their strong performance so far and the expected performance for the remaining year.
• The current investor sentiment for the company stands at 9 buys, 13 holds, and 1 sell.
Intl Flavors & Fragrances on Smartkarma
Analyst coverage of Intl Flavors & Fragrances on Smartkarma reveals positive sentiments and insights from top independent analysts. Baptista Research, a reputable source on the platform, published research reports highlighting key aspects of International Flavors and Fragrances Inc. (IFF). In one report titled “International Flavors & Fragrances (IFF): New Launches“, it was noted that IFF reported strong fourth-quarter and full-year 2023 earnings, with notable growth in sales and EBITDA despite a reported sales decline. This underscores the company’s operational resilience and positive performance.
In another report titled “International Flavors & Fragrances (IFF): What Are Its Biggest Growth Catalysts? – Financial Forecasts“, Baptista Research discussed IFF’s impressive performance in the previous quarter, showcasing a rebound in company-wide volume and strategic moves to optimize its portfolio and capital structure. The sale of Lucas Meyer Cosmetics to Clariant for $810 million was highlighted as a significant step, reflecting IFF’s focus on driving growth and maximizing value for its stakeholders.
A look at Intl Flavors & Fragrances Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 4 | |
| Dividend | 4 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
International Flavors & Fragrances Inc., a company that specializes in creating flavors and fragrances for various industries, is positioned well for the long term according to Smartkarma’s Smart Scores. With high scores in Value and Dividend, the company demonstrates strong fundamentals and shareholder returns potential. However, its Growth and Resilience scores are moderate, indicating room for improvement in these areas. Despite this, Intl Flavors & Fragrances shows promising Momentum, which suggests positive market sentiment and potential for future growth.
Overall, Intl Flavors & Fragrances Inc. appears to be a solid investment option with a favorable outlook based on the Smart Scores analysis. Investors may find the company attractive due to its strong value proposition and dividend potential. While there are areas for growth and resilience that could be addressed, the company’s positive momentum indicates a positive trajectory for future performance in the flavors and fragrances industry.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
